Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-8-26
|
pubmed:abstractText |
Incubation of chronic myeloid leukemia (CML) marrow for 10 days in vitro causes a marked and selective loss of very primitive Philadelphia chromosome (Ph)+ as compared with Ph- progenitors. We have autografted 22 patients with CML (16 in first chronic phase [group 1] and 6 with more advanced disease [group 2]) with marrow treated in this way to facilitate restoration of Ph- hematopoiesis after intensive therapy. Hematologic recovery to greater than 0.5 x 10(9)/L neutrophils occurred in 16 patients, and to greater than 20 x 10(9)/L platelets in 15 of 21 evaluable patients at a median of 29 and 48 days postautograft, respectively. Regenerating marrow cells were 100% Ph- in 13 patients and 75% to 94% Ph- in 3. Between 4 and 36 months (median 12) postautograft, Ph+ cells became detectable in all but 1 (who died in remission) of the 13 patients who achieved complete cytogenetic remission. Four of 7 evaluable patients treated with low-dose interferon alpha were returned to complete cytogenetic remission. Thirteen group 1 patients (81%) are alive 1.0 to 5.7 years (median 2.6) after autografting: 4 in complete cytogenetic remission, 2 in hematologic remission, 6 in chronic phase, and 1 in myeloid blast phase. Three group 2 patients (50%) are alive at 2.6, 3.8, and 4.3 years after autografting: 1 in partial cytogenetic remission, 1 in chronic phase, and 1 in accelerated phase. Thus, autografts of cultured marrow can result in prolonged restoration of Ph- hematopoiesis for some patients with CML.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
724-32
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8043861-Adult,
pubmed-meshheading:8043861-Bone Marrow Transplantation,
pubmed-meshheading:8043861-Cells, Cultured,
pubmed-meshheading:8043861-Female,
pubmed-meshheading:8043861-Graft Survival,
pubmed-meshheading:8043861-Hematopoiesis,
pubmed-meshheading:8043861-Humans,
pubmed-meshheading:8043861-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8043861-Leukocyte Count,
pubmed-meshheading:8043861-Male,
pubmed-meshheading:8043861-Middle Aged,
pubmed-meshheading:8043861-Neoplasm Recurrence, Local,
pubmed-meshheading:8043861-Neutrophils,
pubmed-meshheading:8043861-Pilot Projects,
pubmed-meshheading:8043861-Survival Analysis,
pubmed-meshheading:8043861-Time Factors,
pubmed-meshheading:8043861-Transplantation, Autologous
|
pubmed:year |
1994
|
pubmed:articleTitle |
Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study.
|
pubmed:affiliation |
Leukemia/Bone Marrow Transplantation Program of British Columbia, Terry Fox Laboratory, Vancouver Hospital and Health Sciences Centre, BC, Canada.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|